Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity

被引：1
|
作者：
Le Tourneau, Christophe
Hoimes, Christopher J.
Zarwan, Corrine
Wong, Deborah Jean Lee
Bauer, Sebastian
Wermke, Martin
Claus, Rainer
Chin, Kevin M.
von Heydebreck, Anja
Cuillerot, Jean-Marie
Gulley, James L.
机构：
[1] Inst Curie, Paris, France
[2] Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Lahey Clin Fdn, Burlington, MA USA
[4] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[5] Univ Hosp, West German Canc Ctr, Essen, Germany
[6] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[7] Univ Klinikum Freiburg, Freiburg, Germany
[8] EMD Serono Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
[10] NCI, Genitourinary Malignancies Branch, Lab Tumor Immunol & Biol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.4516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.
    Kaufman, Howard
    Russell, Jeffery Scott
    Hamid, Omid
    Bhatia, Shailender
    Terheyden, Patrick
    D'Angelo, Sandra P.
    Shih, Kent C.
    Lebbe, Celeste
    Linette, Gerald P.
    Milella, Michele
    Brownell, Isaac
    Lewis, Karl D.
    Lorch, Jochen H.
    Chin, Kevin M.
    Mahnke, Lisa
    von Heydebreck, Anja
    Cuillerot, Jean-Marie
    Nghiem, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in a Phase III Trial versus Docetaxel in Patients with Relapsing NSCLC
    Park, Keunchil
    Vansteenkiste, Johan
    Bajars, Marcis
    Helwig, Christoph
    Barlesi, Fabrice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S664 - S664
  • [23] Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
    Nishina, Tomohiro
    Shitara, Kohei
    Iwasa, Satoru
    Hironaka, Shuichi
    Muro, Kei
    Esaki, Taito
    Satoh, Taroh
    Yamaguchi, Kensei
    Machida, Nozomu
    von Heydebreck, Anja
    Watanabe, Morihiro
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.
    Yamada, Yasuhide
    Nishina, Tomohiro
    Iwasa, Satoru
    Shitara, Kohei
    Muro, Kei
    Esaki, Taito
    Hironaka, Shuichi
    Yamaguchi, Kensei
    Machida, Nozomu
    Satoh, Taroh
    von Heydebreck, Anja
    Achiwa, Hiroyuki
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study
    Ribas, Antoni
    Chow, Laura Q.
    Boyd, Jason Keith
    Long, Georgina V.
    Gorczyca, Michele
    Davis, Craig
    Pavlov, Dmitri
    Thall, Aron D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma
    Larkin, James M. G.
    Gordon, Michael S.
    Thistlethwaite, Fiona
    Nathan, Paul D.
    Rini, Brian I.
    Martignoni, Marcella
    Shnaidman, Michael
    Chiruzzi, Chiara
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors.
    Heery, Christopher Ryan
    Infante, Jeffrey R.
    Iannotti, Nicholas
    Kelly, Karen
    Nikolinakos, Petros
    von Heydebreck, Anja
    Chin, Kevin M.
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.
    Disis, Mary L.
    Patel, Manish R.
    Pant, Shubham
    Infante, Jeffrey R.
    Lockhart, A. Craig
    Kelly, Karen
    Beck, Joseph Thaddeus
    Gordon, Michael S.
    Weiss, Glen J.
    Ejadi, Samuel
    Taylor, Matthew Hiram
    von Heydebreck, Anja
    Chin, Kevin M.
    Cuillerot, Jean-Marie
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.
    Tsang, Kwong-Yok
    Boyerinas, Benjamin
    Jochems, Caroline
    Fantini, Massimo
    Heery, Christopher Ryan
    Madan, Ravi Amrit
    Gulley, James L.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
    Boyerinas, Benjamin
    Jochems, Caroline
    Fantini, Massimo
    Heery, Christopher R.
    Gulley, James L.
    Tsang, Kwong Yok
    Schlom, Jeffrey
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1148 - 1157
12345